Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil

Basit Öğe Kaydı
dc.contributor.authorCinemre, Hakan
dc.contributor.authorBilir, Cemil
dc.contributor.authorGökosmanoğlu, Feyzi
dc.contributor.authorAkdemir, Nermin
dc.contributor.authorErdoğmuş, Beşir
dc.contributor.authorBüyükkaya, Ramazan
dc.date.accessioned2020-04-30T23:21:25Z
dc.date.available2020-04-30T23:21:25Z
dc.date.issued2009
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionBilir, Cemil/0000-0002-1372-4791en_US
dc.descriptionWOS: 000267355300002en_US
dc.descriptionPubMed: 19480735en_US
dc.description.abstractPurpose: Propylthiouracil is one of the thionamides used in the treatment of Graves' disease. The drug has serious side effects and long-term treatment might be needed to achieve remission. We designed this study to evaluate the clinical and thyroid Doppler characteristics that might predict time to remission and treatment failure in propylthiouracil treated Graves' patients. Methods: 26 patients, among 134 presenting to our university hospital outpatient clinic between Feb -July 2007 and with first time diagnosis of clinical thyroid dysfunction, were clinically and ultasonographically diagnosed with Graves' disease. Doppler parameters, serum thyrotropin, free thyroxine and free triiodothyronine were measured at the beginning of the study and thyroid studies were repeated every 4 weeks until remission. Propylthiouracil 300 mg/day was started for each patient at the time of diagnosis and doses were titrated according to repeat thyroid studies. Patients were treated and followed up for 18 months. Results: Treatment failure was associated with smoking (P = 0.001) and male gender (P= 0.037). Stepwise multiple regression analysis revealed that age, free thyroxine and superior thyroid artery flow rate were predictors of time to remission (P= 0.001, 0.002 and 0.003, respectively). Conclusion: The time to remission in Graves patients treated with propylthiouracil can be predicted using age, serum free thyroxine and superior thyroid artery flow rate. This may help early consideration of alternative treatment for the patients requiring prolonged treatment for remission or for those who fail medical treatment. This would decrease unnecessary, long-term propylthiouracil exposure with its serious side effects.en_US
dc.identifier.endpageE205en_US
dc.identifier.issn0147-958X
dc.identifier.issn1488-2353
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageE199en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4191
dc.identifier.volume32en_US
dc.identifier.wosWOS:000267355300002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCanadian Soc Clinical Investigationen_US
dc.relation.ispartofClinical And Investigative Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePredictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracilen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4191.pdf
Boyut:
339.21 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu